Thyroid Eye Disease
Top-line data demonstrate efficacy, safety of teprotumumab for thyroid eye disease
Smokers, women experience proptosis reduction with teprotumumab in thyroid eye disease

High-risk adults with active thyroid eye disease, such as smokers, women and older adults, experienced a reduction in outward bulging of the eye at 24 weeks that was similar to adults at lower risk for the disease, according to findings accepted for presentation at the Endocrine Society Annual Meeting.
Immunovant’s thyroid eye disease treatment shows positive phase 2a results
Top stories in endocrinology: Blood test estimates final menstrual period, FDA OKs novel thyroid eye disease treatment
Teprotumumab improves proptosis, quality of life for adults with thyroid eye disease

Adults with thyroid eye disease assigned the human monoclonal antibody teprotumumab were significantly more likely to experience a meaningful improvement in proptosis after 21 weeks of treatment compared with those who received placebo, according to findings from a randomized controlled trial published in The New England Journal of Medicine.